The Lp(a) Letdown and Tumors After Gene Therapy

Friday, November 13, 2026

In today's episode, Dr. Jennifer Lincoln (@drjenniferlincoln) & Eva Johnson cover two large heart drug trials that lowered markers but not events. They break down Lp(a)HORIZON, which tested pelacarsen, and ZEUS, which tested ziltivekimab. They explain why moving a risk marker is not the same as changing outcomes. Plus: they also discuss an FDA investigation into tumors after the SMA gene therapy Zolgensma, what monitoring may mean for practice, an NFL star's scary neck injury, and more. 

Coverage Timeline:

(00:00) This Week’s Headlines (01:44) Pelacarsen: Big Drop, No Benefit (03:03) ZEUS Falls Flat (05:24) Gene Therapy’s Tumor Risk (08:05) Plasma Hack, AI Prior Auth & Statin Nudges (09:45) Jack Campbell’s Recovery

Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email [email protected].

Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources

Medlines is a Human Content Production